SynDevRx
is a Massachusetts-based biopharmaceutical company that develops polymer-based drug conjugates for the treatment of cancer and metabolic dysfunction... Read moreSynDevRx
is a Massachusetts-based biopharmaceutical company that develops polymer-based drug conjugates for the treatment of cancer and metabolic dysfunction... Read more
News
May 19, 2026
EIN Presswire
Press Release: SynDevRx : SynDevRx to Present AMELIA -1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer
Feb 19, 2026
EIN Presswire
Press Release: SynDevRx : SynDevRx Publishes Data On Evexomostat Establishing New Metabo-Oncology Therapeutic Modality
Dec 02, 2025
EIN Presswire
Press Release: SynDevRx : Memorial Sloan Kettering to Present Clinical Data from The ARETHA-1 Trial of SynDevRx's Evexomostat in mTNBC at SABCS
Jan 09, 2025
EIN Presswire
Press Release: SynDevRx : $1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor 'Evexomostat'
Sep 30, 2024
SEC
SynDevRx: SynDevRx , Inc. raised 29.3 M through equity funding
Mar 28, 2024
Accesswire
SynDevRx: Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones
Sep 19, 2023
Accesswire
Press Release: SynDevRx : First Patient Treated in Innovative Clinical Study 'Amelia-1', Testing the Novel Investigational Drug Evexomostat Plus a PI3K Inhibitor in Late-Stage Breast Cancer Patients
Apr 14, 2023
Accesswire
Press Release: SynDevRx : New Experimental Treatment for Prostate Cancer Revealed at AACR
Jun 01, 2022
Business Wire
Press Release: SynDevRx : New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance
Dec 08, 2021
MarketScreener
SynDevRx: SynDevRx To Present Pre-Clinical Combination Data of Evexomostat (SDX-7320) with Capivasertib (AZD-5363) During The 2021 San Antonio Breast Cancer Symposium
SynDevRx Competitors
1
2
3
4
5
6
7
8
9
10